Assessing the transition from intravenous to subcutaneous delivery of rituximab: Benefits for payers, health care professionals, and patients with lymphoma.
PLoS ONE, 2022, 17, e0261336
This is an overview of where and by who this paper has been cited.
Non-profit projects normally ask for donations. We don't. We will survive one way or another. If you wish to help us, please spread the word to let more people use this service.
It is delightful to see our efforts are useful to a broad range of researchers.